SBFM Q4 2022 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4M+4528.9% YoY

Gross Profit

$1M37.8% margin

Operating Income

-$23M-593.0% margin

Net Income

-$24M-596.8% margin

EPS (Diluted)

$-1.04

QoQ Revenue Growth

+2866.7%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$3M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$30M

Total Liabilities

$8M

Stockholders' Equity

$22M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$85,118	+4528.9%
Gross Profit	$1M	$23,829	+6157.1%
Operating Income	-$23M	-$280,000	-8244.3%
Net Income	-$24M	$667,116	-3624.4%